SCHEMBL6280938

SCHEMBL6280938

COc1ccc(S(=O)(=O)n2cc(/C(=N\NC(=N)N)C3CC3)c3cc(Cl)ccc32)cc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
DRD2 P14416 1/20 0.47
SLC6A2 P23975 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
SLC6A4 P31645 1/20 0.47
HTR7 P34969 1/20 0.47
HRH1 P35367 1/20 0.47
ADRA1B P35368 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HTR6 P50406 13/20 0.44
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6280940 1.00 KCNH2 (0.47) KCNH2CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6278481 0.91 HTR6 (0.42) KCNH2CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6278478 0.91 HTR6 (0.42) KCNH2CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6281043 0.89 HTR6 (0.51) HTR6MEN1KMT2ALMNAPDE4A
SCHEMBL6281048 0.89 HTR6 (0.51) HTR6MEN1KMT2ALMNAPDE4A
SCHEMBL6286983 0.87 HTR6 (0.45) KCNH2CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6286990 0.87 HTR6 (0.45) KCNH2CYP3A4CYP2D6DRD2SLC6A2
SCHEMBL6278622 0.86 HTR6 (0.44) HTR2AHTR7HTR6MEN1KMT2A
SCHEMBL6278624 0.86 HTR6 (0.44) HTR2AHTR7HTR6MEN1KMT2A
SCHEMBL6284287 0.86 HTR6 (0.41) KCNH2CYP3A4CYP2D6DRD2SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US claimed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US claimed
US-6906095-B2 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-06-14 US disclosed
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH 2004-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002527-A1 Indolylalkylidenehydrazine-carboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR2A KCNH2 588/4885CYP3A4 1789/4885CYP2D6 333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.